St. Jude Reference #SJ-11-0018
Researchers at St. Jude have developed a modified Sendai virus vaccine and imaging vector which can be used to make kits for a modified Enders strain Sendai viral vector vaccine. The immunogenic vector can be used in any in vitro or in vivo system, and the discovery includes vectors for imaging virus growth, location and transmission. This genetically modified Sendai Virus would be useful for delivery of chimeric vaccine antigens to prevent conditions such as diseases caused by respiratory syncytial virus (RSV) or parainfluenza virus type 1 (croup). Potential candidates include intranasal or parenteral vaccines for both RSV and hPIV-1 concurrently in pediatrics, elderly, etc. (or other vaccines with different inserts), with the potential benefit of an increased safety margin when using enders strain compared to Z strain sequences.
Sendai, virus, vaccine, imaging, vector, immunogenic
Granted patents or published applications
Issued US Patent applications 9,637,758; and 10,329,584; and most all of the EU
Related scientific references
We are currently seeking a partner to commercialize this vaccine. Contact: firstname.lastname@example.org
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.